Resultados de Búsqueda
Do recommend sofosbuvir–velpatasvir–voxilaprevir as an option for treating chronic hepatitis C in adults, only if it is used as specified in table 1 and the company provides the drug at the same ...
NICE
National Institute for Health and Clinical Excellence (NICE)
It is recommended that the decision to treat and prescribing decisions are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, to prioritise treatment for people with the highest unmet clinical need. These recommendations are not intended to affect treatment with sofosbuvir–velpatasvir–voxilaprevir that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to ...
ver más ... 2018Do recommend Glecaprevir–pibrentasvir, within its marketing authorisation, as an option for treating chronic hepatitis C in adults, only if the company provides the drug at the same price or lower ...
NICE
National Institute for Health and Clinical Excellence (NICE)
It is recommended that the decision to treat and prescribing decisions are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, to prioritise treatment for people with the highest unmet clinical need. Current treatment options for chronic hepatitis C depend on genotype, cirrhosis status and treatment history. Glecaprevir–pibrentasvir is suitable for all genotypes and has a shorter treatment duration than most other direct-acting antiviral ...
ver más ... 2018It is recommended to use Tofacitinib, with methotrexate, as an option for treating active psoriatic arthritis in adults, on determinanted conditions.
NICE
National Institute for Health and Clinical Excellence (NICE
Tofacitinib, with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or TNF‑alpha inhibitors ...
ver más ... 2018It is recommended Ixekizumab alone or with methotrexate is recommended as an option to treat active psoriatic arthritis in adults, only on determinantet conditions:
NICE
National Institute for Health and Clinical Excellence (NICE
Ixekizumab alone, or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults, only if: it is used as described in NICE's technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or the person has had a tumour necrosis factor (TNF)-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after the first 12 weeks ...
ver más ... 2018Autologous chondrocyte implantation (ACI) using chondrosphere is recommended as an option for treating symptomatic articular cartilage defects of the femoral condyle and patella of the knee ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Only if: the person has not had previous surgery to repair articular cartilage defects there is minimal osteoarthritic damage to the knee (as assessed by clinicians experienced in investigating knee cartilage damage using a validated measure for knee osteoarthritis) and the defect is over 2 cm2. Current surgical treatments for symptomatic articular cartilage defects of the knee include microfracture, ACI and mosaicplasty. Clinical trial results show that ACI using chondrosphere is as ...
ver más ... 2018